Acetylated Polyamine Biomarker Detection for HIV Neurocognitive Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliable molecular diagnostic biomarkers for detecting and monitoring HIV-1-associated neurocognitive disorders (HAND), relying on neurological exams and imaging, which are not sufficient for accurate diagnosis and progression assessment.
Innovation Solution
Detecting elevated levels of acetyl spermine and acetyl spermidine in cerebrospinal fluid (CSF) using HPLC, mass spectroscopy, or chromogenic sensing, comparing these levels to control samples or standard values to indicate the presence and severity of HAND.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If neurological exams and brain MRI scans are used for diagnosis, then diagnostic coverage is broad, but measurement precision and reliability are insufficient
Solution Approach 1:
The patent changes the diagnostic parameter from anatomical/functional assessments (MRI, neurological exams) to molecular biomarker concentrations (acetylated polyamines in CSF). This parameter shift enables precise quantification of neurocognitive disorder severity through measurable chemical markers, directly resolving the contradiction between diagnostic accuracy and method complexity.
Solution Approach 2:
The patent replaces mechanical/physical diagnostic methods (neurological exams, MRI imaging) with biochemical analysis methods (detecting acetylated polyamine levels in CSF). This substitution uses chemical markers instead of physical assessments, achieving higher measurement precision while simplifying the diagnostic workflow through standardized laboratory testing.
2Loss of information
If current diagnostic methods are used, then no molecular biomarkers are available, but this results in loss of information for disease monitoring
Solution Approach 1:
The patent extracts specific molecular biomarkers (acetylated polyamines) from the complex biological system of the CNS and measures their concentrations in CSF. This extraction approach isolates the key information carriers (acetylated spermine, acetylated spermidine) that reflect disease state, preventing information loss and enabling quantitative monitoring of HAND progression.
Solution Approach 2:
The patent uses acetylated polyamines as intermediary molecules that mediate between the underlying neurocognitive pathology and the diagnostic measurement. These biomarkers serve as information intermediaries, translating complex neural damage into measurable chemical concentrations, thereby preserving and conveying disease progression information.
3Productivity
If exclusion-based diagnosis is used, then broad differential diagnosis is possible, but productivity and diagnostic speed are reduced
Solution Approach 1:
The patent performs preliminary identification of specific molecular biomarker patterns (elevated acetylated polyamines) that pre-indicate HAND diagnosis. This preliminary action allows clinicians to quickly identify HAND cases before proceeding to comprehensive exclusion-based differential diagnosis, thereby increasing diagnostic speed while maintaining reliability through the specificity of the biomarker signature.
Solution Approach 2:
The patent establishes a feedback mechanism where acetylated polyamine levels provide direct information about disease presence and severity. This feedback replaces the slow iterative process of exclusion-based diagnosis with immediate biomarker-based confirmation, enhancing both diagnostic productivity and reliability through objective molecular evidence.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a reliable method for detecting mild neurocognitive disturbance and HIV-associated dementia, monitoring progression, and staging HAND, enhancing diagnostic accuracy and clinical management.
Implementation Method 1
detecting the level of acetyl spermine and acetyl spermidine in a cerebrospinal fluid test sample of the patient
Implementation Method 2
detecting the level of acetyl spermine and acetyl spermidine in a cerebrospinal fluid test sample of the patient
Data Source
AI summary
Provided is a method of detecting mild neurocognitive disturbance (MNCD) or HIV associated dementia (HAD) in a patient comprising detecting the level of acetyl spermine and/or acetyl spermidine from a cerebrospinal fluid test sample of the patient; and comparing the level of acetyl spermine and/or acetyl spermidine in the test sample to the level of the acetyl spermine and/or acetyl spermidine in a cerebrospinal fluid control sample or to a control value for lack of neurocognitive impairment, MNCD or HAD; wherein an elevated level of acetyl spermine and/or acetyl spermidine in the test sample as compared to the level in the control sample or a control value for lack of neurocognitive impairment, or a level of acetyl spermine and/or acetyl spermidine that is similar to that of a control value for MNCD or HAD, indicates that the patient suffers from MNCD or HAD. Also provided are methods for measuring the progression of an HIV-1-associated neurocognitive disorder, as well as methods for staging such a disorder.